Alkermes ALKS Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's noncash or part noncash acquisition value of liabilities assumed1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's noncash or part noncash acquisition value of liabilities assumed1?
- Alkermes (ALKS) reported noncash or part noncash acquisition value of liabilities assumed1 of $5.56M in Q1 2026.
- How has Alkermes's noncash or part noncash acquisition value of liabilities assumed1 changed year-over-year?
- Alkermes's noncash or part noncash acquisition value of liabilities assumed1 decreased by 6.0% year-over-year, from $5.91M to $5.56M.
- What does noncash or part noncash acquisition value of liabilities assumed1 mean?
- The value of debt or other obligations taken on by the company during an acquisition that did not require an immediate cash payment.
- How do you interpret noncash or part noncash acquisition value of liabilities assumed1?
- An increase signals active inorganic growth through acquisitions where the company is leveraging its balance sheet or assuming existing liabilities rather than using cash reserves.
- How does noncash or part noncash acquisition value of liabilities assumed1 compare across companies?
- Commonly found in the supplemental cash flow disclosures of biotech and pharmaceutical firms that frequently acquire intellectual property or smaller entities.